Free Trial
NASDAQ:INAB

IN8bio (INAB) Stock Price, News & Analysis

IN8bio logo
$2.17 -0.03 (-1.36%)
Closing price 04:00 PM Eastern
Extended Trading
$2.26 +0.09 (+3.92%)
As of 05:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About IN8bio Stock (NASDAQ:INAB)

Key Stats

Today's Range
$2.13
$2.23
50-Day Range
$2.07
$4.89
52-Week Range
$2.05
$26.76
Volume
104,638 shs
Average Volume
108,134 shs
Market Capitalization
$6.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$180.00
Consensus Rating
Buy

Company Overview

IN8bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
69th Percentile Overall Score

INAB MarketRank™: 

IN8bio scored higher than 69% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    IN8bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    IN8bio has received no research coverage in the past 90 days.

  • Read more about IN8bio's stock forecast and price target.
  • Earnings Growth

    Earnings for IN8bio are expected to grow in the coming year, from ($0.56) to ($0.22) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of IN8bio is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of IN8bio is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    IN8bio has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about IN8bio's valuation and earnings.
  • Percentage of Shares Shorted

    7.82% of the float of IN8bio has been sold short.
  • Short Interest Ratio / Days to Cover

    IN8bio has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in IN8bio has recently decreased by 5.88%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    IN8bio does not currently pay a dividend.

  • Dividend Growth

    IN8bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.82% of the float of IN8bio has been sold short.
  • Short Interest Ratio / Days to Cover

    IN8bio has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in IN8bio has recently decreased by 5.88%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    IN8bio has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • Search Interest

    Only 3 people have searched for INAB on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.
  • MarketBeat Follows

    11 people have added IN8bio to their MarketBeat watchlist in the last 30 days. This is an increase of 120% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, IN8bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    15.50% of the stock of IN8bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    92.05% of the stock of IN8bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about IN8bio's insider trading history.
Receive INAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IN8bio and its competitors with MarketBeat's FREE daily newsletter.

INAB Stock News Headlines

A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
See More Headlines

INAB Stock Analysis - Frequently Asked Questions

IN8bio's stock was trading at $7.7160 at the beginning of the year. Since then, INAB stock has decreased by 71.9% and is now trading at $2.17.

IN8bio, Inc. (NASDAQ:INAB) announced its quarterly earnings results on Thursday, May, 8th. The company reported ($2.10) earnings per share for the quarter, missing analysts' consensus estimates of ($1.80) by $0.30.

IN8bio's stock reverse split before market open on Friday, June 6th 2025.The 1-30 reverse split was announced on Thursday, June 5th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 5th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

IN8bio (INAB) raised $44 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 4,000,000 shares at a price of $10.00-$12.00 per share. B. Riley Securities acted as the underwriter for the IPO.

Shares of INAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that IN8bio investors own include NVIDIA (NVDA), Ford Motor (F), GitLab (GTLB), Cognition Therapeutics (CGTX), CrowdStrike (CRWD), Chevron (CVX) and Meta Platforms (META).

Company Calendar

Last Earnings
5/08/2025
Today
7/18/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:INAB
CIK
1740279
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

High Price Target
$180.00
Low Price Target
$180.00
Potential Upside/Downside
+8,194.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($13.57)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$30.44 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-218.85%
Return on Assets
-139.59%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
4.30
Quick Ratio
4.30

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.00 per share
Price / Book
0.36

Miscellaneous

Outstanding Shares
3,030,000
Free Float
2,557,000
Market Cap
$6.58 million
Optionable
Not Optionable
Beta
N/A
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:INAB) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners